Pravin Dugel Sells 20,056 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 20,056 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $8.28, for a total transaction of $166,063.68. Following the completion of the sale, the insider owned 3,013,022 shares of the company’s stock, valued at $24,947,822.16. This trade represents a 0.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Pravin Dugel also recently made the following trade(s):

• On Thursday, February 12th, Pravin Dugel sold 124,882 shares of Ocular Therapeutix stock. The stock was sold at an average price of $9.04, for a total transaction of $1,128,933.28.

Ocular Therapeutix Trading Up 0.9%

NASDAQ OCUL opened at $9.59 on Friday. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $2.09 billion, a P/E ratio of -6.66 and a beta of 0.90. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $16.44. The firm has a 50-day moving average price of $10.38 and a 200 day moving average price of $11.59.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $13.25 million for the quarter, compared to analyst estimates of $16.13 million. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The firm’s revenue for the quarter was down 22.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.29) EPS. Equities research analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OCUL. Pale Fire Capital SE grew its position in shares of Ocular Therapeutix by 20.7% in the second quarter. Pale Fire Capital SE now owns 530,135 shares of the biopharmaceutical company’s stock valued at $4,920,000 after purchasing an additional 90,748 shares during the period. Saturn V Capital Management LP lifted its position in Ocular Therapeutix by 21.8% during the second quarter. Saturn V Capital Management LP now owns 728,576 shares of the biopharmaceutical company’s stock worth $6,761,000 after buying an additional 130,385 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Ocular Therapeutix in the 2nd quarter worth about $342,000. Allianz Asset Management GmbH boosted its stake in Ocular Therapeutix by 63.2% in the 2nd quarter. Allianz Asset Management GmbH now owns 61,200 shares of the biopharmaceutical company’s stock worth $568,000 after buying an additional 23,700 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its holdings in Ocular Therapeutix by 33.6% in the 2nd quarter. Panagora Asset Management Inc. now owns 296,546 shares of the biopharmaceutical company’s stock valued at $2,752,000 after buying an additional 74,542 shares during the period. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Ocular Therapeutix

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Director Richard Lindstrom bought 60,229 shares at ~ $7.66, increasing his stake ~32% — a notable insider purchase that signals confidence and provides direct demand support. SEC Filing – Lindstrom Form 4
• Positive Sentiment: Ocular will present detailed SOL‑1 data at the Macula Society meeting and host investor events — favorable readouts or constructive management commentary could be a major catalyst for the stock and offset recent weakness. SOL‑1 Presentation
• Positive Sentiment: Large institutional holders have been adding to positions (Vanguard, Avoro, TCG Crossover, Adage, Geode), which supports longer‑term demand even amid short‑term volatility. MarketBeat Institutional Summary
• Neutral Sentiment: Analyst coverage remains mixed-to-positive overall (consensus “Moderate Buy,” average target ~$23.78) — this keeps a bullish case intact but creates a wide range of expectations that earnings or SOL‑1 commentary could swing stock directionally. MarketBeat Summary
• Neutral Sentiment: Smaller, individual insider sales (e.g., Nadia Waheed sold 3,510 shares at ~$7.74) appear modest relative to major holdings and are unlikely alone to change long‑term conviction. SEC Filing – Waheed Form 4
• Negative Sentiment: Several executives/directors sold shares on Feb. 23 (Sanjay Nayak, Jeffrey Heier, Peter Kaiser and Pravin Dugel — Dugel sold 20,056 shares) at roughly $8.28; clustered insider selling increases available float and weighs on near‑term sentiment. SEC Filing – Dugel Form 4
• Negative Sentiment: Short interest jumped ~27.8% in February to ~14.7M shares (~6.9% of the float), elevating bearish pressure and the potential for sharper downside or volatile moves ahead of catalysts. (Days‑to‑cover ~3.0.)
• Negative Sentiment: Needham trimmed its price target to $18 (from $20), a downgrade that could temper enthusiasm among some growth/biotech investors despite other higher targets. Needham Price Target Cut

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on OCUL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Thursday, January 22nd. TD Cowen reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Wall Street Zen upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $30.00 price target on shares of Ocular Therapeutix in a research report on Thursday, February 5th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.78.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.